Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Non-progressing cancer patients have persistent B cell responses expressing shared antibody paratopes that target public tumor antigens.

DeFalco J, Harbell M, Manning-Bog A, Baia G, Scholz A, Millare B, Sumi M, Zhang D, Chu F, Dowd C, Zuno-Mitchell P, Kim D, Leung Y, Jiang S, Tang X, Williamson KS, Chen X, Carroll SM, Espiritu Santo G, Haaser N, Nguyen N, Giladi E, Minor D, Tan YC, Sokolove JB, Steinman L, Serafini TA, Cavet G, Greenberg NM, Glanville J, Volkmuth W, Emerling DE, Robinson WH.

Clin Immunol. 2018 Feb;187:37-45. doi: 10.1016/j.clim.2017.10.002. Epub 2017 Oct 12.

2.

s-SHIP expression identifies a subset of murine basal prostate cells as neonatal stem cells.

Brocqueville G, Chmelar RS, Bauderlique-Le Roy H, Deruy E, Tian L, Vessella RL, Greenberg NM, Rohrschneider LR, Bourette RP.

Oncotarget. 2016 May 17;7(20):29228-44. doi: 10.18632/oncotarget.8709.

3.

Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis.

Liu G, Lu S, Wang X, Page ST, Higano CS, Plymate SR, Greenberg NM, Sun S, Li Z, Wu JD.

J Clin Invest. 2013 Oct;123(10):4410-22. doi: 10.1172/JCI69369. Epub 2013 Sep 9.

4.

β4 Integrin signaling induces expansion of prostate tumor progenitors.

Yoshioka T, Otero J, Chen Y, Kim YM, Koutcher JA, Satagopan J, Reuter V, Carver B, de Stanchina E, Enomoto K, Greenberg NM, Scardino PT, Scher HI, Sawyers CL, Giancotti FG.

J Clin Invest. 2013 Feb;123(2):682-99. doi: 10.1172/JCI60720. Epub 2013 Jan 25.

5.

Cell-intrinsic abrogation of TGF-β signaling delays but does not prevent dysfunction of self/tumor-specific CD8 T cells in a murine model of autochthonous prostate cancer.

Chou CK, Schietinger A, Liggitt HD, Tan X, Funk S, Freeman GJ, Ratliff TL, Greenberg NM, Greenberg PD.

J Immunol. 2012 Oct 15;189(8):3936-46. doi: 10.4049/jimmunol.1201415. Epub 2012 Sep 14.

6.

A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease.

Thompson VC, Day TK, Bianco-Miotto T, Selth LA, Han G, Thomas M, Buchanan G, Scher HI, Nelson CC; Australian Prostate Cancer BioResource, Greenberg NM, Butler LM, Tilley WD.

Int J Cancer. 2012 Aug 1;131(3):662-72. doi: 10.1002/ijc.26414. Epub 2012 Jan 24.

7.

Characterization of the oncogenic activity of the novel TRIM59 gene in mouse cancer models.

Valiyeva F, Jiang F, Elmaadawi A, Moussa M, Yee SP, Raptis L, Izawa JI, Yang BB, Greenberg NM, Wang F, Xuan JW.

Mol Cancer Ther. 2011 Jul;10(7):1229-40. doi: 10.1158/1535-7163.MCT-11-0077. Epub 2011 May 18.

8.

Hypoexpression and epigenetic regulation of candidate tumor suppressor gene CADM-2 in human prostate cancer.

Chang G, Xu S, Dhir R, Chandran U, O'Keefe DS, Greenberg NM, Gingrich JR.

Clin Cancer Res. 2010 Nov 15;16(22):5390-401. doi: 10.1158/1078-0432.CCR-10-1461. Epub 2010 Nov 9.

9.

Differential regulation of insulin-like growth factor-I receptor gene expression by wild type and mutant androgen receptor in prostate cancer cells.

Schayek H, Seti H, Greenberg NM, Sun S, Werner H, Plymate SR.

Mol Cell Endocrinol. 2010 Jul 29;323(2):239-45. doi: 10.1016/j.mce.2010.04.017. Epub 2010 Apr 24.

10.

Cutting Edge: Tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells.

Shafer-Weaver KA, Anderson MJ, Stagliano K, Malyguine A, Greenberg NM, Hurwitz AA.

J Immunol. 2009 Oct 15;183(8):4848-52. doi: 10.4049/jimmunol.0900848.

11.

Molecular targeted enhanced ultrasound imaging of flk1 reveals diagnosis and prognosis potential in a genetically engineered mouse prostate cancer model.

Xuan JW, Bygrave M, Valiyeva F, Moussa M, Izawa JI, Bauman GS, Klibanov A, Wang F, Greenberg NM, Fenster A.

Mol Imaging. 2009 Jul-Aug;8(4):209-20.

PMID:
19728975
12.

Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells.

Shafer-Weaver KA, Watkins SK, Anderson MJ, Draper LJ, Malyguine A, Alvord WG, Greenberg NM, Hurwitz AA.

Cancer Res. 2009 Aug 1;69(15):6256-64. doi: 10.1158/0008-5472.CAN-08-4516. Epub 2009 Jul 21. Retraction in: Cancer Res. 2016 Apr 15;76(8):2490.

13.

Chinese medicinal herb Scutellaria barbata modulates apoptosis and cell survival in murine and human prostate cancer cells and tumor development in TRAMP mice.

Wong BY, Nguyen DL, Lin T, Wong HH, Cavalcante A, Greenberg NM, Hausted RP, Zheng J.

Eur J Cancer Prev. 2009 Aug;18(4):331-41. doi: 10.1097/CEJ.0b013e32832c3859.

PMID:
19444125
14.

Conditional deletion of insulin-like growth factor-I receptor in prostate epithelium.

Sutherland BW, Knoblaugh SE, Kaplan-Lefko PJ, Wang F, Holzenberger M, Greenberg NM.

Cancer Res. 2008 May 1;68(9):3495-504. doi: 10.1158/0008-5472.CAN-07-6531.

15.

Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer.

Bertilaccio MT, Grioni M, Sutherland BW, Degl'Innocenti E, Freschi M, Jachetti E, Greenberg NM, Corti A, Bellone M.

Prostate. 2008 Jul 1;68(10):1105-15. doi: 10.1002/pros.20775.

PMID:
18437689
16.

The TRAMP mouse as a model for prostate cancer.

Hurwitz AA, Foster BA, Allison JP, Greenberg NM, Kwon ED.

Curr Protoc Immunol. 2001 Nov;Chapter 20:Unit 20.5. doi: 10.1002/0471142735.im2005s45.

PMID:
18432778
17.

NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy.

Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, Knoblaugh S, Cado D, Greenberg NM, Raulet DH.

Immunity. 2008 Apr;28(4):571-80. doi: 10.1016/j.immuni.2008.02.016. Erratum in: Immunity. 2008 May;28(5):723. Greenberg, Norman R [corrected to Greenberg, Norman M].

18.

SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade.

Fassò M, Waitz R, Hou Y, Rim T, Greenberg NM, Shastri N, Fong L, Allison JP.

Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3509-14. doi: 10.1073/pnas.0712269105. Epub 2008 Feb 26.

19.

The current state of preclinical prostate cancer animal models.

Pienta KJ, Abate-Shen C, Agus DB, Attar RM, Chung LW, Greenberg NM, Hahn WC, Isaacs JT, Navone NM, Peehl DM, Simons JW, Solit DB, Soule HR, VanDyke TA, Weber MJ, Wu L, Vessella RL.

Prostate. 2008 May 1;68(6):629-39. doi: 10.1002/pros.20726.

20.

Role of epithelial cell fibroblast growth factor receptor substrate 2alpha in prostate development, regeneration and tumorigenesis.

Zhang Y, Zhang J, Lin Y, Lan Y, Lin C, Xuan JW, Shen MM, McKeehan WL, Greenberg NM, Wang F.

Development. 2008 Feb;135(4):775-84. doi: 10.1242/dev.009910. Epub 2008 Jan 9.

21.

Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model.

Huss WJ, Gray DR, Tavakoli K, Marmillion ME, Durham LE, Johnson MA, Greenberg NM, Smith GJ.

Neoplasia. 2007 Nov;9(11):938-50.

22.

Enforced epithelial expression of IGF-1 causes hyperplastic prostate growth while negative selection is requisite for spontaneous metastogenesis.

Kaplan-Lefko PJ, Sutherland BW, Evangelou AI, Hadsell DL, Barrios RJ, Foster BA, Demayo F, Greenberg NM.

Oncogene. 2008 May 1;27(20):2868-76. Epub 2007 Nov 19.

PMID:
18026134
23.

Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model.

Raina K, Blouin MJ, Singh RP, Majeed N, Deep G, Varghese L, Glodé LM, Greenberg NM, Hwang D, Cohen P, Pollak MN, Agarwal R.

Cancer Res. 2007 Nov 15;67(22):11083-91.

24.

Phytosterol Pygeum africanum regulates prostate cancer in vitro and in vivo.

Shenouda NS, Sakla MS, Newton LG, Besch-Williford C, Greenberg NM, MacDonald RS, Lubahn DB.

Endocrine. 2007 Feb;31(1):72-81.

PMID:
17709901
25.

Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci.

Veiseh M, Gabikian P, Bahrami SB, Veiseh O, Zhang M, Hackman RC, Ravanpay AC, Stroud MR, Kusuma Y, Hansen SJ, Kwok D, Munoz NM, Sze RW, Grady WM, Greenberg NM, Ellenbogen RG, Olson JM.

Cancer Res. 2007 Jul 15;67(14):6882-8.

26.

Genetic ablation of the amplified-in-breast cancer 1 inhibits spontaneous prostate cancer progression in mice.

Chung AC, Zhou S, Liao L, Tien JC, Greenberg NM, Xu J.

Cancer Res. 2007 Jun 15;67(12):5965-75.

27.

Functional neoangiogenesis imaging of genetically engineered mouse prostate cancer using three-dimensional power Doppler ultrasound.

Xuan JW, Bygrave M, Jiang H, Valiyeva F, Dunmore-Buyze J, Holdsworth DW, Izawa JI, Bauman G, Moussa M, Winter SF, Greenberg NM, Chin JL, Drangova M, Fenster A, Lacefield JC.

Cancer Res. 2007 Mar 15;67(6):2830-9.

28.

Effects of dietary saw palmetto on the prostate of transgenic adenocarcinoma of the mouse prostate model (TRAMP).

Wadsworth TL, Worstell TR, Greenberg NM, Roselli CE.

Prostate. 2007 May 1;67(6):661-73.

PMID:
17342743
29.

Conditional activation of FGFR1 in the prostate epithelium induces angiogenesis with concomitant differential regulation of Ang-1 and Ang-2.

Winter SF, Acevedo VD, Gangula RD, Freeman KW, Spencer DM, Greenberg NM.

Oncogene. 2007 Jul 26;26(34):4897-907. Epub 2007 Feb 12.

PMID:
17297442
30.

Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer.

Anderson MJ, Shafer-Weaver K, Greenberg NM, Hurwitz AA.

J Immunol. 2007 Feb 1;178(3):1268-76. Erratum in: J Immunol. 2007 Nov 15;179(10):7184.

31.

Bub1 up-regulation and hyperphosphorylation promote malignant transformation in SV40 tag-induced transgenic mouse models.

Guo C, Wu G, Chin JL, Bauman G, Moussa M, Wang F, Greenberg NM, Taylor SS, Xuan JW.

Mol Cancer Res. 2006 Dec;4(12):957-69.

32.

Androgen receptor coregulators and their involvement in the development and progression of prostate cancer.

Chmelar R, Buchanan G, Need EF, Tilley W, Greenberg NM.

Int J Cancer. 2007 Feb 15;120(4):719-33. Review.

33.

Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.

Morgenbesser SD, McLaren RP, Richards B, Zhang M, Akmaev VR, Winter SF, Mineva ND, Kaplan-Lefko PJ, Foster BA, Cook BP, Dufault MR, Cao X, Wang CJ, Teicher BA, Klinger KW, Greenberg NM, Madden SL.

Prostate. 2007 Jan 1;67(1):83-106.

PMID:
17013881
34.

Blockade of transforming growth factor-{beta} signaling in tumor-reactive CD8(+) T cells activates the antitumor immune response cycle.

Zhang Q, Yang XJ, Kundu SD, Pins M, Javonovic B, Meyer R, Kim SJ, Greenberg NM, Kuzel T, Meagher R, Guo Y, Lee C.

Mol Cancer Ther. 2006 Jul;5(7):1733-43.

35.
36.

MHC class I and class II molecules are expressed in both human and mouse prostate tumor microenvironment.

Nanda NK, Birch L, Greenberg NM, Prins GS.

Prostate. 2006 Sep 1;66(12):1275-84.

37.

Targeting Aurora kinases for the treatment of prostate cancer.

Lee EC, Frolov A, Li R, Ayala G, Greenberg NM.

Cancer Res. 2006 May 15;66(10):4996-5002.

38.

Establishment of a serum tumor marker for preclinical trials of mouse prostate cancer models.

Huizen IV, Wu G, Moussa M, Chin JL, Fenster A, Lacefield JC, Sakai H, Greenberg NM, Xuan JW.

Clin Cancer Res. 2005 Nov 1;11(21):7911-9.

39.

Infiltration of tumor-reactive transforming growth factor-beta insensitive CD8+ T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells.

Zhang Q, Jang TL, Yang X, Park I, Meyer RE, Kundu S, Pins M, Javonovic B, Kuzel T, Kim SJ, Van Parijs L, Smith N, Wong L, Greenberg NM, Guo Y, Lee C.

Prostate. 2006 Feb 15;66(3):235-47.

PMID:
16173028
40.

beta1A integrin expression is required for type 1 insulin-like growth factor receptor mitogenic and transforming activities and localization to focal contacts.

Goel HL, Breen M, Zhang J, Das I, Aznavoorian-Cheshire S, Greenberg NM, Elgavish A, Languino LR.

Cancer Res. 2005 Aug 1;65(15):6692-700.

41.

Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells.

Huss WJ, Gray DR, Greenberg NM, Mohler JL, Smith GJ.

Cancer Res. 2005 Aug 1;65(15):6640-50.

42.

Androgens and prostate cancer: are the descriptors valid?

Roy-Burman P, Tindall DJ, Robins DM, Greenberg NM, Hendrix MJ, Mohla S, Getzenberg RH, Isaacs JT, Pienta KJ.

Cancer Biol Ther. 2005 Jan;4(1):4-5.

PMID:
16052746
43.

A new three-dimensional ultrasound microimaging technology for preclinical studies using a transgenic prostate cancer mouse model.

Wirtzfeld LA, Wu G, Bygrave M, Yamasaki Y, Sakai H, Moussa M, Izawa JI, Downey DB, Greenberg NM, Fenster A, Xuan JW, Lacefield JC.

Cancer Res. 2005 Jul 15;65(14):6337-45.

44.

A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model.

Majeed N, Blouin MJ, Kaplan-Lefko PJ, Barry-Shaw J, Greenberg NM, Gaudreau P, Bismar TA, Pollak M.

Oncogene. 2005 Jul 7;24(29):4736-40.

PMID:
15870705
45.

Dietary genistein improves survival and reduces expression of osteopontin in the prostate of transgenic mice with prostatic adenocarcinoma (TRAMP).

Mentor-Marcel R, Lamartiniere CA, Eltoum IA, Greenberg NM, Elgavish A.

J Nutr. 2005 May;135(5):989-95.

PMID:
15867270
46.

Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model.

Wu GJ, Fu P, Chiang CF, Huss WJ, Greenberg NM, Wu MW.

J Urol. 2005 May;173(5):1778-83.

PMID:
15821586
47.

Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.

Zhang Q, Yang X, Pins M, Javonovic B, Kuzel T, Kim SJ, Parijs LV, Greenberg NM, Liu V, Guo Y, Lee C.

Cancer Res. 2005 Mar 1;65(5):1761-9.

48.

Mutation of the androgen receptor causes oncogenic transformation of the prostate.

Han G, Buchanan G, Ittmann M, Harris JM, Yu X, Demayo FJ, Tilley W, Greenberg NM.

Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1151-6. Epub 2005 Jan 18.

49.

Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization.

Degl'Innocenti E, Grioni M, Boni A, Camporeale A, Bertilaccio MT, Freschi M, Monno A, Arcelloni C, Greenberg NM, Bellone M.

Eur J Immunol. 2005 Jan;35(1):66-75.

50.

Conditional deletion of Rb causes early stage prostate cancer.

Maddison LA, Sutherland BW, Barrios RJ, Greenberg NM.

Cancer Res. 2004 Sep 1;64(17):6018-25.

Supplemental Content

Loading ...
Support Center